Jorge Benito, MD
Psychiatry · South Miami, FLNPI 1356384606
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (40.2%), education and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Medical Device Business Services, Inc. at 37.0% of the total. Reporting peaked in 2024 at $1,893 and has fallen 71.5% since, to $539 in 2025.
Across 119 payments — averaging $43.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$2K
- Stryker$1K
- Johnson & Johnson$667
- Alkermes, Inc.$491
- Teva Pharmaceuticals USA, Inc.$283
- Otsuka America Pharmaceutical, Inc.$191
- plus $469 from 6 others
Across 10 payments — averaging $3461.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$25K
- E.r. Squibb & Sons, L.L.C.$10K
What the payments were for
- Travel & lodging$1,07921%
- Food & beverage$2,10340%
- Education$2,04539%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 9 | $1,933 |
| Stryker | 5 | $1,193 |
| Johnson & Johnson | 35 | $667 |
| Alkermes, Inc. | 26 | $491 |
| Teva Pharmaceuticals USA, Inc. | 13 | $283 |
| Otsuka America Pharmaceutical, Inc. | 9 | $191 |
| AbbVie(2 entities) | 8 | $167 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $166 |
| E.r. Squibb & Sons, L.L.C. | 3 | $71 |
| Luye Pharma (USA) Ltd. | 2 | $35 |
| Indivior Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,227 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 24 | $68,388 |
| Invega SustennaPaliperidone Palmitate | 20 | $58,488 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $7,783 |
| Aripiprazole | 26 | $5,590 |
| Fluphenazine Decanoate | 14 | $1,683 |
| Quetiapine Fumarate | 62 | $1,411 |
| Divalproex Sodium | 52 | $1,030 |
| Risperidone | 71 | $932 |
| Trazodone Hcl | 98 | $813 |
| Haloperidol Decanoate | 20 | $781 |
| Clozapine | 18 | $721 |
| Olanzapine | 39 | $643 |
| Escitalopram Oxalate | 49 | $607 |
| Temazepam | 34 | $484 |
| Paroxetine Hcl | 18 | $441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $191 | $68,38824 claims |
| Johnson & JohnsonInvega Sustenna | $667 | $58,48820 claims |
| AbbVieNamzaric | $167 | $7,78312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in South Miami
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.